Introduction

Intravenous (IV) administration remains the gold standard for therapeutic antibodies, accounting for approximately 70% of approved products due to its 100% systemic bioavailability and capacity for high-dose delivery. Literature confirms that while alternative routes are expanding, the rapid onset of action and predictable pharmacokinetics of the IV route are indispensable for acute oncology and infectious disease treatments. Creative Biolabs leverages decades of biophysical expertise to transform vulnerable lead candidates into robust drug products suitable for the rigorous demands of clinical infusion environments.

Fig.1 Intravenous (IV) infusion is the most used administration routes of mAb therapy.¹

Intravenous (IV) Antibody Formulations

Intravenous antibody formulations are pivotal in both research and advanced clinical care. Precision formulation development is the bridge between a laboratory success and a viable clinical product. A well-engineered formulation ensures patient safety by preventing infusion reactions triggered by subvisible particles. It also guarantees dosing accuracy, particularly for low-dose therapeutics where surface adsorption could otherwise lead to significant underdosing.

Challenges of IV Antibody Formulation Development

Intravenous (IV) antibody formulation development faces a distinct set of challenges, primarily centered on in-use stability during dilution, protein adsorption, and oxidative degradation.

• Diluent Incompatibility: Many mAbs formulated at acidic pH undergo rapid, insoluble aggregation when mixed with common IV diluents like 5% dextrose.
• Isoelectric Precipitation: Antibodies can interact with serum proteins (e.g., complement proteins C3, C4) at the blood-IV interface, leading to isoelectric precipitation if the formulation pH and ionic strength are not perfectly balanced.
• Surfactant Degradation: Trace host-cell lipases can degrade Polysorbate 20 / 80, leading to free fatty acid particles and loss of protein stabilization during infusion.
• Adsorption at Low Doses: High-potency antibodies at low concentrations (< 0.5 mg/mL) are susceptible to losing up to 40% of their mass due to adsorption onto IV bags and administration tubing.

Fig.2 Commonly employed excipients in high-concentration monoclonal antibody formulations.¹

Our Intravenous (IV) Antibody Formulation Development Service

Intravenous (IV) antibody formulation development is a critical process aimed at creating a stable, safe, and effective liquid or lyophilized drug product. The process focuses on stabilizing the protein against stressors like aggregation, chemical degradation, and shear, typically ensuring the final product is compatible with IV bag diluents. Creative Biolabs' intravenous (IV) antibody formulation development service provides the scientific rigor and analytical depth required to move your therapeutic from the bench to the bedside. By addressing challenges in pH balance, ionic strength, and surfactant stability early, we mitigate risks and ensure clinical success.

Workflow of Intravenous (IV) Antibody Formulation Development Service

Contact Us

Creative Biolabs combines 20 years of biologics experience with state-of-the-art analytical platforms. We provide solutions to intravenous (IV) antibody formulation development. Our unique use of Flow Imaging (FI) as an orthogonal method ensures we detect transparent protein aggregates that traditional light obscuration might miss, guaranteeing superior safety profiles. Contact us for more information and to discuss your project.

FAQs

Loading case studies...

For research use only. Not intended for any clinical use.